These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28034876)

  • 1. An indel polymorphism within pre-miR3131 confers risk for hepatocellular carcinoma.
    Wang C; Li L; Yin Z; Zhang Q; Zhao H; Tao R; Wang S; Hu S; He Y; Wang D; Li C; Zhang S; Xu J; Jiang X; Zhu S; Gao Y
    Carcinogenesis; 2017 Feb; 38(2):168-176. PubMed ID: 28034876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma.
    Tao R; Hu S; Wang S; Zhou X; Zhang Q; Wang C; Zhao X; Zhou W; Zhang S; Li C; Zhao H; He Y; Zhu S; Xu J; Jiang Y; Li L; Gao Y
    Carcinogenesis; 2015 Oct; 36(10):1136-43. PubMed ID: 26163879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between an insertion/deletion polymorphism within 3'UTR of SGSM3 and risk of hepatocellular carcinoma.
    Wang C; Zhao H; Zhao X; Wan J; Wang D; Bi W; Jiang X; Gao Y
    Tumour Biol; 2014 Jan; 35(1):295-301. PubMed ID: 23918301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study.
    Akkız H; Bayram S; Bekar A; Akgöllü E; Ulger Y
    J Viral Hepat; 2011 Jul; 18(7):e399-407. PubMed ID: 21692953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.
    Chen L; Guan H; Gu C; Cao Y; Shao J; Wang F
    Tumour Biol; 2016 Feb; 37(2):2497-507. PubMed ID: 26385772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3' untranslated region confers risk for hepatocellular carcinoma.
    Gao Y; He Y; Ding J; Wu K; Hu B; Liu Y; Wu Y; Guo B; Shen Y; Landi D; Landi S; Zhou Y; Liu H
    Carcinogenesis; 2009 Dec; 30(12):2064-9. PubMed ID: 19917630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-194 acts as a prognostic marker and inhibits proliferation in hepatocellular carcinoma by targeting MAP4K4.
    Zhao Y; Li F; Zhang X; Liu A; Qi J; Cui H; Zhao P
    Int J Clin Exp Pathol; 2015; 8(10):12446-54. PubMed ID: 26722431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-520f inhibits hepatocellular carcinoma cell proliferation and invasion by targeting TM4SF1.
    Du X; Fan W; Chen Y
    Gene; 2018 May; 657():30-38. PubMed ID: 29505836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk.
    Zhu Z; Gao X; He Y; Zhao H; Yu Q; Jiang D; Zhang P; Ma X; Huang H; Dong D; Wan J; Gu Z; Jiang X; Yu L; Gao Y
    Cancer Res; 2012 Dec; 72(23):6163-72. PubMed ID: 23026137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
    Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
    Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinoma development in Turkish population: a case-control study.
    Akkız H; Bayram S; Bekar A; Akgöllü E; Usküdar O; Sandıkçı M
    Gene; 2011 Oct; 486(1-2):104-9. PubMed ID: 21807077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells.
    He J; Zhao K; Zheng L; Xu Z; Gong W; Chen S; Shen X; Huang G; Gao M; Zeng Y; Zhang Y; He F
    Mol Cancer; 2015 Aug; 14():163. PubMed ID: 26302777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-κB pathway.
    Zhao L; Zhang Y
    Biochem Biophys Res Commun; 2015 Feb; 457(3):370-7. PubMed ID: 25580008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival.
    Chen M; Hu W; Xiong CL; Qu Z; Yin CQ; Wang YH; Luo CL; Guan Q; Yuan CH; Wang FB
    Oncotarget; 2016 Dec; 7(49):80751-80764. PubMed ID: 27811373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
    Tian Z; Jiang H; Liu Y; Huang Y; Xiong X; Wu H; Dai X
    Exp Cell Res; 2016 May; 343(2):135-147. PubMed ID: 27090017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma.
    Lian J; Jing Y; Dong Q; Huan L; Chen D; Bao C; Wang Q; Zhao F; Li J; Yao M; Qin L; Liang L; He X
    Oncotarget; 2016 Jan; 7(3):2672-83. PubMed ID: 26684241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73.
    Zhao J; Xu T; Wang F; Cai W; Chen L
    Biomed Pharmacother; 2017 Jun; 90():744-751. PubMed ID: 28419971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p.
    Wang Y; Sun B; Sun H; Zhao X; Wang X; Zhao N; Zhang Y; Li Y; Gu Q; Liu F; Shao B; An J
    Tumour Biol; 2016 Aug; 37(8):10965-79. PubMed ID: 26891666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling.
    Chang RM; Xu JF; Fang F; Yang H; Yang LY
    Tumour Biol; 2016 Aug; 37(8):10609-19. PubMed ID: 26861561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.
    Shi KQ; Lin Z; Chen XJ; Song M; Wang YQ; Cai YJ; Yang NB; Zheng MH; Dong JZ; Zhang L; Chen YP
    Oncotarget; 2015 Sep; 6(28):25093-108. PubMed ID: 26231037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.